This company has shut down. Sonnet BioTherapeutics is no longer operating — its last tracked round was a Post-IPO Equity in 2024.
Explore the Startup GraveyardSonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action.
Sonnet BioTherapeutics has raised $3.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.
Sonnet BioTherapeutics is headquartered in Princeton, United States.
Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action.
Sonnet BioTherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sonnet BioTherapeutics — Funding & Investors." VCBacked, December 9, 2024, https://www.vcbacked.co/company/sonnet-biotherapeutics. Accessed August 13, 2026.
VCBacked. (2024). Sonnet BioTherapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/sonnet-biotherapeutics
{{cite web |title=Sonnet BioTherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sonnet-biotherapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated